好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Challenges of MRI in Clinical Practice
Multiple Sclerosis
P11 - Poster Session 11 (11:45 AM-12:45 PM)
3-008

The purpose of this analysis is to gain insights into some of the challenges faced in a clinical setting when using magnetic resonance imaging (MRI) for the monitoring of multiple sclerosis (MS) disease activity. 

MRI is considered by many to be the gold standard for the diagnosis and monitoring of MS. Imaging metrics are often the primary outcome measures for clinical trials assessing the efficacy of new treatments.  While there have been significant technological advances in imaging techniques in research, practical application in a clinical setting has lagged for numerous reasons including cost and accessibility.   Differences in equipment, sequence methodologies, and the interpretation can also affect the quality of the reports and the overall usefulness of MRI as a tool. 

During a timeframe spanning 2020-2022, imaging metrics were collected from a database search of a single private practice with six practitioners in Salt Lake City, UT, USA serving several MS patients throughout the Intermountain West.

Approximately 200 brain MRI reports were input into the clinic database monthly with about 120 of those being ordered by directly by clinic and the remaining coming from referrals.  In a single month, MRI images came from over 50 different facilities.  Roughly 60% of those images were from the local hospital network, Intermountain Healthcare, which is comprised of over more than twenty different locations.  Another 20% of scans came from the stand-alone imaging center, Mountain Medical Imaging, and another 20% of scans were from imaging centers representing less than 5% of the scans by volume. 

With an increasing number of MRI techniques and facilities available it is more important than ever for sites to be aware of the various factors that may affect the quality of imaging they use to evaluate and treat MS patients in their care. 

Authors/Disclosures
Cortnee Roman, NP, DAAN (Rocky Mountain MS Clinic)
PRESENTER
Ms. Roman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myer Squibb. Ms. Roman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Ms. Roman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Ms. Roman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Ms. Roman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genzyme. Ms. Roman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Ms. Roman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myer Squibb/Celgene.
Tamara Hoyt (Rocky Mountain MS Research Group) Ms. Hoyt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono.
Angelene Christensen (Rocky Mountain MS Research Group) Ms. Christensen has a non-compensated relationship as a project manager with InterPro Bioscience that is relevant to AAN interests or activities.
Sydney Vivanco (Rocky Mountain MS Clinic) Mrs. Vivanco has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. Mrs. Vivanco has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Mrs. Vivanco has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Mrs. Vivanco has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Mrs. Vivanco has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
John F. Foley, MD, FAAN (Rocky Mountain MS Clinic) The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave. Dr. Foley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Foley has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Foley has stock in InterPRO Bioscience. The institution of Dr. Foley has received research support from Biogen. The institution of Dr. Foley has received research support from Novartis. The institution of Dr. Foley has received research support from Octave. The institution of Dr. Foley has received research support from Genentech. The institution of Dr. Foley has received research support from Imstem. The institution of Dr. Foley has received research support from Aegir.